TotalMarketCap

Regenxbio

RGNXNasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$487.177 M

$7.38 -4.28%

Close of 6 Nov 2026

As of 6 Nov 2026, Regenxbio (RGNX) has a market capitalization of $487.2M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$170.4M

#2327 by revenue

Earnings

-$193.9M

Loss-making

Shares outstanding

66,122,600

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #64SurrozenSRZN$517.4M
  2. #65SL ScienceSLBT$504.7M
  3. #66RegenxbioRGNX$487.2M
  4. #67Electra TherapeuticsETRA$449.4M
  5. #68Editas MedicineEDIT$390.9M

What if Regenxbio were worth as much as…

Open the what-if tool →

Gold $28.2T

$427,745.92

Per share 57,960× higher

Bitcoin $1.53T

$23,144.59

Per share 3,136× higher

Apple $5.02T

$75,981.52

Per share 10,296× higher

Or at a round number

$1.00B$2.00B$5.00B$10.0B

Where these numbers come from

Share counts and financials for Regenxbio are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.